Drug Profile
Research programme: Nell1 protein therapeutics - NellOne Therapeutics
Latest Information Update: 28 Apr 2022
Price :
$50
*
At a glance
- Originator NellOne Therapeutics
- Class Anti-inflammatories; Anti-ischaemics; Proteins
- Mechanism of Action NELL1 protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Research COVID 2019 infections
- No development reported Myocardial infarction; Wounds
Most Recent Events
- 28 Apr 2022 No recent reports of development identified for preclinical development in Myocardial-infarction in USA (Parenteral)
- 28 Apr 2022 No recent reports of development identified for preclinical development in Wounds in USA (Parenteral)
- 18 May 2020 NellOne Therapeutics files a provisional patent application for use of its NELL1 signaling protein for preventing or treating respiratory viral infections including COVID-2019 infections